Legal & General Group Plc Raises Holdings in FibroGen Inc (FGEN)

Legal & General Group Plc raised its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 16.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,049 shares of the biopharmaceutical company’s stock after buying an additional 4,351 shares during the period. Legal & General Group Plc’s holdings in FibroGen were worth $1,437,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of FibroGen by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after buying an additional 125,186 shares during the period. Vanguard Group Inc boosted its stake in shares of FibroGen by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after buying an additional 125,186 shares during the period. Hillhouse Capital Advisors Ltd. acquired a new stake in shares of FibroGen during the 4th quarter valued at $92,712,000. First Trust Advisors LP boosted its stake in shares of FibroGen by 3.3% during the 4th quarter. First Trust Advisors LP now owns 1,707,422 shares of the biopharmaceutical company’s stock valued at $79,019,000 after buying an additional 55,209 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of FibroGen by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,158,474 shares of the biopharmaceutical company’s stock valued at $70,378,000 after buying an additional 97,070 shares during the period. 66.58% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on FGEN shares. Stifel Nicolaus started coverage on shares of FibroGen in a research note on Monday, February 11th. They issued a “buy” rating and a $71.00 price objective for the company. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 22nd. Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 9th. ValuEngine lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 14th. Finally, TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research note on Friday, March 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $71.17.

In related news, Director Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock in a transaction on Monday, April 15th. The shares were sold at an average price of $48.09, for a total value of $192,360.00. Following the transaction, the director now owns 27,700 shares in the company, valued at approximately $1,332,093. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 18,400 shares of FibroGen stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $46.81, for a total transaction of $861,304.00. Following the completion of the transaction, the chief executive officer now owns 2,550,176 shares in the company, valued at approximately $119,373,738.56. The disclosure for this sale can be found here. Insiders sold a total of 328,721 shares of company stock worth $17,983,268 in the last quarter. Insiders own 8.96% of the company’s stock.

FGEN stock opened at $47.21 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.75 and a quick ratio of 7.75. FibroGen Inc has a 1 year low of $37.27 and a 1 year high of $68.55. The firm has a market capitalization of $4.04 billion, a P/E ratio of -45.83 and a beta of 1.72.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.40. The firm had revenue of $108.05 million for the quarter, compared to the consensus estimate of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. The business’s quarterly revenue was up 251.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.27) EPS. Equities analysts forecast that FibroGen Inc will post -0.97 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/legal-general-group-plc-raises-holdings-in-fibrogen-inc-fgen.html.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: What is a stock buyback?

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.